绥美凯用法用量

GlaxoSmithKline (GSK) announced on January 20 that its controlled joint venture ViiV Healthcare1’s single-pill compound preparation (chemical name: dolutegravir) for the treatment of HIV, which is based on the new generation integrase inhibitor Tevicai (chemical name: dolutegravir), was officially launched in mainland China. This is the first single-pill compound preparation with a complete treatment plan in the field of HIV treatment in mainland China. As an innovative single-pill compound preparation with obvious clinical therapeutic advantages, Suimeikai can provide great convenience for the treatment of HIV-infected patients.

Suimeikai is the only three-in-one compound drug with dolutegravir (DTG) as the core. It has the characteristics of high efficacy, good tolerance, high resistance barrier, and few drug interactions. One tablet per day can significantly reduce the medication burden of HIV-infected patients, thereby improving patients' medication compliance and significantly improving their quality of life.

At present, Suimeikai has been approved for marketing in 50 countries and regions, and has been recommended by many authoritative academic institutions and authoritative guidelines in Europe and the United States as the first-line treatment of choice for patients with newly diagnosed HIV infection. At present, global antiviral treatment is gradually entering the era of integrase inhibitors, and fixed-dose compound preparations have also become the trend of future treatment. Integrase inhibitors have four main characteristics: stronger antiviral effects, smaller toxic side effects, fewer drug interactions, and less prone to drug resistance. As a single-pill compound drug containing a new generation of integrase inhibitor DTG, the launch of Suimeikai will bring a more convenient and efficient integrase inhibitor compound combination to Chinese HIV-infected patients, which is a major advancement in China's existing antiviral treatment.

Following the launch of Tivicai, a new HIV treatment drug last year, this is another new HIV drug from GSK approved for sale in mainland China. GSK has been bringing innovative, high-quality treatment solutions to HIV-infected people in China since 1999. Shuangtaizhi is GSK's first approved HIV antiviral treatment drug in China.